Integrated BioPharma, Inc. (INBP) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Integrated BioPharma, Inc. (INBP), Consumer Defensive sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 40/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Integrated BioPharma, Inc. (INBP) Tüketici İşletmesi Genel Bakışı
Integrated BioPharma, Inc. focuses on the manufacturing and distribution of vitamins, nutritional supplements, and herbal products, operating primarily in the United States and Luxembourg. With a presence in both contract manufacturing and direct distribution, the company caters to distributors, multilevel marketers, and specialized healthcare providers within the consumer defensive sector.
Yatırım Tezi
Integrated BioPharma, Inc. presents a complex investment case, given its small market capitalization of $0.01 billion and negative profit margin of -0.4%. The company's low gross margin of 7.8% and negative ROE of -1.0% indicate profitability challenges. While the beta of 0.52 suggests lower volatility compared to the market, the high debt-to-equity ratio of 2.55 raises concerns about financial leverage. A key consideration is the company's ability to generate free cash flow, which currently stands at $0.00 billion. Potential investors should carefully evaluate the company's turnaround strategy and its ability to improve profitability and cash flow generation. Upcoming catalysts may include new product launches or expansion into new markets, but these need to be weighed against the potential risks associated with the company's financial performance.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $0.01B indicates a micro-cap company with potential for high growth but also higher risk.
- Negative Profit Margin of -0.4% highlights challenges in achieving profitability.
- Gross Margin of 7.8% is relatively low compared to industry averages, suggesting potential inefficiencies in production or pricing.
- Debt-to-Equity Ratio of 2.55 indicates a highly leveraged balance sheet, which could increase financial risk.
- Beta of 0.52 suggests the stock is less volatile than the overall market.
Rakipler & Benzerleri
Güçlü Yönler
- Established manufacturing capabilities.
- Existing distribution network.
- Experience in contract manufacturing.
- Presence in both US and Luxembourg markets.
Zayıflıklar
- Low profit margin.
- High debt-to-equity ratio.
- Small market capitalization.
- Limited brand recognition.
Katalizörler
- Upcoming: Potential new product launches in the vitamin and supplement sector.
- Upcoming: Expansion into new geographic markets, particularly in Asia.
- Ongoing: Increasing consumer demand for health and wellness products.
- Ongoing: Growth in the contract manufacturing market for nutraceuticals.
- Ongoing: Shift towards e-commerce and direct-to-consumer sales channels.
Riskler
- Potential: Intense competition from larger, more established players.
- Potential: Fluctuations in raw material prices.
- Potential: Changes in regulations governing the nutraceuticals industry.
- Ongoing: Low profit margins and high debt levels.
- Ongoing: Limited liquidity and price volatility due to OTC listing.
Büyüme Fırsatları
- Expansion of Contract Manufacturing Services: Integrated BioPharma can capitalize on the growing demand for private label and white label supplements by expanding its contract manufacturing services. The global contract manufacturing market for nutraceuticals is projected to reach $95 billion by 2028. By investing in advanced manufacturing technologies and quality control processes, INBP can attract more clients and increase its production volume, leading to higher revenue and improved profitability. This expansion could be realized within the next 2-3 years.
- New Product Development and Innovation: Introducing innovative and scientifically-backed nutritional supplements can drive revenue growth. The market for personalized nutrition is expanding rapidly, with consumers seeking customized solutions for their health needs. Integrated BioPharma can invest in research and development to create new products targeting specific health conditions or demographic groups. Successful product launches could significantly boost sales within the next 1-2 years.
- Geographic Expansion into New Markets: Expanding its distribution network beyond the United States and Luxembourg can unlock new growth opportunities. Emerging markets in Asia and Latin America are experiencing increasing demand for vitamins and supplements. By establishing partnerships with local distributors or setting up its own sales channels, Integrated BioPharma can tap into these high-growth markets. This expansion could take 3-5 years to fully materialize.
- Strategic Acquisitions and Partnerships: Acquiring complementary businesses or forming strategic partnerships can enhance Integrated BioPharma's capabilities and market reach. For example, acquiring a company with expertise in e-commerce or digital marketing can improve its online sales channels. Partnering with a research institution can accelerate its product development efforts. Such strategic moves could yield significant benefits within the next 2-3 years.
- Focus on E-commerce and Direct-to-Consumer Sales: The shift towards online shopping presents a significant growth opportunity for Integrated BioPharma. By investing in its e-commerce platform and digital marketing capabilities, the company can reach a wider customer base and increase its direct-to-consumer sales. The online channel offers higher margins and greater control over the customer experience. This strategy can be implemented and generate results within the next 1-2 years.
Fırsatlar
- Expansion of contract manufacturing services.
- New product development and innovation.
- Geographic expansion into emerging markets.
- Increased focus on e-commerce and direct-to-consumer sales.
Tehditler
- Intense competition in the nutraceuticals market.
- Changing consumer preferences and regulatory requirements.
- Fluctuations in raw material prices.
- Potential product liability claims.
Rekabet Avantajları
- Established manufacturing capabilities.
- Existing distribution network.
- Long-standing relationships with suppliers and customers.
INBP Hakkında
Integrated BioPharma, Inc., incorporated in 1980 and based in Hillside, New Jersey, operates within the consumer defensive sector, specifically in packaged foods. The company focuses on the manufacturing, distribution, marketing, and sale of vitamins, nutritional supplements, and herbal products. Its operations are divided into two segments: Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment produces vitamins and nutritional supplements for distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment provides warehousing and fulfillment services, alongside distributing raw materials. Formerly known as Integrated Health Technologies, Inc., the company has established a presence in the United States and Luxembourg. Integrated BioPharma's business model caters to both B2B and potentially B2C channels, leveraging its manufacturing capabilities to supply a range of health and wellness products. The company's history reflects its evolution within the nutraceuticals market, adapting to changing consumer preferences and distribution models.
Ne Yaparlar
- Manufactures vitamins and nutritional supplements.
- Distributes vitamins, nutritional supplements, and herbal products.
- Markets vitamins, nutritional supplements, and herbal products.
- Offers contract manufacturing services to distributors.
- Provides warehousing and fulfillment services.
- Distributes raw materials for supplement production.
İş Modeli
- Contract manufacturing of vitamins and supplements for other companies.
- Direct distribution of branded and white-label products.
- Warehousing and fulfillment services for nutraceutical businesses.
Sektör Bağlamı
Integrated BioPharma operates in the packaged foods industry, specifically within the vitamins and supplements segment. This market is characterized by increasing consumer awareness of health and wellness, driving demand for nutritional products. The industry is competitive, with established players and emerging brands vying for market share. Trends include personalized nutrition, clean label products, and e-commerce distribution. Integrated BioPharma's focus on contract manufacturing and distribution positions it within the supply chain, serving both large distributors and specialized healthcare providers. The company's success depends on its ability to maintain quality, innovate with new products, and adapt to changing consumer preferences.
Kilit Müşteriler
- Distributors of vitamins and supplements.
- Multilevel marketing companies.
- Specialized healthcare providers.
- Consumers (potentially through retail channels).
Finansallar
Grafik & Bilgi
Integrated BioPharma, Inc. (INBP) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
accessnewswire.com · 11 Şub 2026
-
Stocks That Hit 52-Week Highs On Wednesday
· 19 Şub 2020
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
INBP için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
INBP için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, INBP'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
INBP OTC Piyasa Bilgileri
The OTCQX tier represents the highest tier of the OTC market, signifying companies that meet certain financial standards, demonstrate compliance with U.S. securities laws, and are current in their disclosure obligations. Unlike companies listed on the NYSE or NASDAQ, OTCQX-listed companies are not subject to the same stringent listing requirements, such as minimum share price and market capitalization thresholds. However, OTCQX provides a platform for established and growing companies to access a wider investor base while benefiting from streamlined regulatory processes compared to lower OTC tiers.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited liquidity compared to major exchanges.
- Wider bid-ask spreads, potentially increasing transaction costs.
- Less stringent regulatory oversight than NYSE or NASDAQ.
- Potential for greater price volatility.
- Information asymmetry due to less analyst coverage.
- Verify the company's financial statements and SEC filings.
- Assess the company's management team and corporate governance practices.
- Analyze the company's competitive landscape and market position.
- Evaluate the company's growth prospects and potential catalysts.
- Review the company's risk factors and potential liabilities.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- OTCQX tier listing indicates a higher level of compliance and disclosure.
- Current disclosure status suggests a commitment to transparency.
- Long operating history since incorporation in 1980.
- Audited financial statements (verify availability).
- Positive news coverage or industry recognition (if any).
Integrated BioPharma, Inc. Hissesi: Cevaplanan Temel Sorular
INBP için değerlendirilmesi gereken temel faktörler nelerdir?
Integrated BioPharma, Inc. (INBP) şu anda yapay zeka skoru 40/100, düşük puanı gösteriyor. Temel güçlü yan: Established manufacturing capabilities.. İzlenmesi gereken birincil risk: Potential: Intense competition from larger, more established players.. Bu bir finansal tavsiye değildir.
INBP MoonshotScore'u nedir?
INBP şu anda MoonshotScore'da 40/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
INBP verileri ne sıklıkla güncellenir?
INBP fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler INBP hakkında ne diyor?
INBP için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
INBP'a yatırım yapmanın riskleri nelerdir?
INBP için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from larger, more established players.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
INBP'ın P/E oranı nedir?
INBP için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için INBP'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
INBP aşırı değerli mi, yoksa düşük değerli mi?
Integrated BioPharma, Inc. (INBP)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
INBP'ın temettü verimi nedir?
Integrated BioPharma, Inc. (INBP) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited analyst coverage may affect the availability of information.
- OTC market stocks carry higher risk than exchange-listed stocks.